Summarized by Masters of Longevity from Longevity Docs News.
FDA added a non-arteritic anterior ischemic optic neuropathy warning to all GLP-1 labels.
Key Takeaways
- A small trial signal was reported but causality has not been established.
- Real-world data showed higher NAION incidence versus DPP-4 inhibitors.
- Patients with prior NAION are at higher risk of recurrence.
